-
Adults (18-64 years)
-
Elderly (≥65 years)
-
Healthcare workers
-
Hospital
-
SARS-CoV-2
-
Respiratory syncytial virus
-
Influenza virus
-
Respiratory syncytial virus infection
-
Influenza
-
COVID-19
-
General population
-
Infants (<1 year)
-
Hospital
-
Emergency department
-
SARS-CoV-2
-
Respiratory syncytial virus
-
Influenza virus
-
Respiratory syncytial virus infection
-
Influenza
-
COVID-19
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
Emergency department
-
SARS-CoV-2
-
Respiratory syncytial virus
-
Influenza virus
-
Respiratory syncytial virus infection
-
Influenza
-
COVID-19
-
General population
-
Infants (<1 year)
-
Hospital
-
SARS-CoV-2
-
Respiratory syncytial virus
-
Influenza virus
-
Respiratory syncytial virus infection
-
Influenza
-
COVID-19
-
Pharmacological intervention
-
Monoclonal antibodies
-
Nirsevimab
-
General population
-
Infants (<1 year)
-
Children (1-11 years)
-
Hospital
-
Primary care
-
SARS-CoV-2
-
Respiratory syncytial virus
-
Influenza virus
-
Human metapneumovirus
-
Respiratory syncytial virus infection
-
Influenza
-
COVID-19
-
Human metapneumovirus infection
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Primary care
-
SARS-CoV-2
-
Respiratory syncytial virus
-
Influenza virus
-
Respiratory syncytial virus infection
-
Influenza
-
COVID-19
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Infants (<1 year)
-
Adolescents (12-17 years)
-
Children (1-11 years)
-
Hospital
-
Non-hospital health centre
-
SARS-CoV-2
-
Respiratory syncytial virus
-
Influenza virus
-
Adenovirus
-
Metapneumovirus
-
Parainfluenza Virus
-
Rhinovirus
-
Respiratory syncytial virus infection
-
Influenza
-
COVID-19
-
Adenovirus infection
-
Metapneumovirus infection
-
Parainfluenza virus infection
-
Rhinovirus infection
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
SARS-CoV-2
-
Respiratory syncytial virus
-
Influenza virus
-
Respiratory syncytial virus infection
-
Influenza
-
COVID-19